HDFC MUTUAL FUND
BHAROSA APNO KA

INDIAN CANCER SOCIETY
RISE AGAINST CANCER

HDFC Charity Fund for Cancer Cure (Feb 2030)

NFO PERIOD: 16th to 30th November 2026

#InvestInOthers



Refer disclaimers on slide 19

HDFC Mutual Fund: SEBI Registration Number: MF/044/00/6



One new diagnosis in India.*

In the Next 40 Minutes

110+

Indians will hear the words **“It’s cancer.”**

Most will hear about the cost before they hear about the cure.

The next patient is already waiting.

*14,61,427 estimated new cancer cases in India in 2022 ≈ 2.8 a minute ≈ one every 22 seconds ≈ 111 in 40 minutes. Source: ICMR-NCDIR National Cancer Registry Programme

Refer disclaimers on slide 19

Giving isn't new to India. It's who we are.

Dāna

Giving as a duty, across every faith.

Gandhian Trusteeship

Wealth held in trust for society.

It has always been in our nature for thousands of years.

Refer disclaimers on slide 19

Learn. Earn. Return.

LEARN	EARN	RETURN
Build capability	Build wealth	Give back

SDG 3 UN Sustainable Development Goal: **Good Health and Well-being**

“The true measure of life is not how much we earn, but how much we return.”

Refer disclaimers on slide 19

Philanthropy as an asset class

HDFC MUTUAL FUND
BHAROSA APNO KA

15 YEARS OF PROVEN IMPACT
A series of dedicated funds for Cancer Cure



₹292.41 cr

contributed to the Indian Cancer Society, 2011–2026 (As on Sep 2026)

₹109.80 cr through four Cancer Cure Funds + ₹182.61 cr directly from HDFC AMC

2011

HDFC Debt Fund for Cancer Cure

₹77 cr corpus

₹12.77 cr to ICS

Matured in 2014

2014

HDFC Debt Fund for Cancer Cure

₹175 cr corpus

₹25.87 cr to ICS

Matured in 2017

2017

HDFC Charity Fund for Cancer Cure

₹308 cr corpus

₹45.55 cr to ICS

Matured in 2020

2023

HDFC Charity Fund for Cancer Cure (A Fixed Maturity Plan)

₹189 cr corpus

₹25.61 cr to ICS

Matures on 23rd Nov 2026

Source: HDFC AMC, Indian Cancer Society. ₹109.80 cr = sum of the four funds' contributions; HDFC AMC direct contribution 2013–2026.
Refer disclaimers on slide 19

Over 17,000 lives touched since 2011

HDFC MUTUAL FUND
BHAROSA APNO KA

17,435
patients funded*

₹273.28 cr
disbursed for treatment*

22
hospitals empanelled

Nearly 1 in 4 patients funded was a child aged 15 or under.
More than half were women.



Source: Indian Cancer Society. *As on 31st Aug 26 Age: 0–15 yrs 25%; gender: female 56%

Refer disclaimers on slide 19

Who is eligible, for what, and how much

WHO

- Underprivileged patients
- Patients should be registered under general category in one of ICS empanelled hospital
- Projected survival rate 50% for adult patients and 70% for paediatric patients
- Only Indian citizens

WHAT IT COVERS

- Surgery
- Chemotherapy
- Radiation therapy
- Supportive care
- Prosthesis

HOW MUCH

₹5 lakh
maximum per patient*

₹8 lakh
max. for bone marrow transplant


*Family income should not exceed Rs 4 lakh per year

Refer disclaimers on slide 19

CCF Empanelled Hospitals

HDFC MUTUAL FUND
BHAROSA APNO KA

City	Name of the Hospital	Logo
Srinagar	Sher-i-Kashmir Institute of Medical Sciences (SKIMS)	
Jalandhar	Patel Hospital (PATEL)	
Delhi	Rajiv Gandhi Cancer Institute (RGCI)	
Varanasi	Homi Bhaba Cancer Hospital (HBCH) Mahamanah Pandit Madan Mohan Malviya Cancer Centre (MPMMCC)	
Patna	Mahavir Cancer Sanstha and Research Center (MCSRC)	
Silchar	Cachar Cancer Hospital & Research Center (CCHRC)	
Betul	Padhar Hospital (PH)	
Raipur	Balco Medical Centre (BMC)	
Goral Ahmedabad	Kailash Cancer Hospital (KCH) Gujarat Cancer Research Institute (GCRI)	
Mumbai Chiplun	Tata Memorial Hospital (TMH) BKL Walawalkar Hospital (BKL)	
Bengaluru	Sri Shankara Cancer Hospital & Research Center (SSCHRC)	
Hyderabad	Basavatarakam Indo American Cancer Hospital (INDO)	
Chennai Vellore	Cancer Institute (CI) Christian Medical College (CMC)	
Thiruvananthapuram	Regional Cancer Centre (RCC)	
Kolkata	Chittaranjan National Cancer Institute	
Visakhapatnam	Homi Bhabha Cancer Hospital & Research Centre (HBCH-VZ)	
Mullanpur/ Sangrur	Homi Bhabha Cancer Hospital & Research Centre (HBCH - PB)	
Bhubaneswar	Bagchi Sri Shankara Cancer Centre and Research Institute	



Data as on Sep 2026

Refer disclaimers on slide 19

Indian Cancer Society

INDIAN CANCER SOCIETY
RISE AGAINST CANCER

Founded in 1951 by Dr D.J. Jussawalla and Naval Tata - India's first voluntary, non-profit, national organisation for cancer awareness, detection, cure and survivorship.

Awareness & Prevention

Nationwide awareness of risk factors, prevention and regular check-ups.

Early detection

Detection centres and mobile camps, especially for the underprivileged.

Diagnostics and Treatment Funding

Funds treatment for poor cancer patients across India.

Survivorship and Rehabilitation

Accommodation, rehabilitation and survivor support groups.

Also the only NGO running a population-based cancer registry (Mumbai, Pune, Nagpur, Aurangabad), and publisher of the Indian Journal of Cancer.

Refer disclaimers on slide 19

GOVERNING ADVISORY COUNCIL

Reviews and sanction cases by an independent council

HDFC MUTUAL FUND
BHAROSA APNO KA

Chaired by Mrs Usha Thorat • Former Deputy Governor, Reserve Bank of India

Mr M K Sharma
Former Vice Chairman, Hindustan Unilever

Mr Navneet Munot
MD & CEO, HDFC AMC

Mr Hari L Mundra
Former ED, Hindustan Unilever

Mr Ramesh Swaminathan
Ex Director & CFO, Lupin

Dr Purna Kurkure
Senior Advisor, Clinical Collegium for Oncology Services, Narayana Health Group, Head, Division of Pediatric, Haemato- Oncology & BMT, SRCC Children's Hospital.

Mr Kewal Nohria
Former Chairman & MD, Crompton Greaves

Mr Gautam Chakravarti
CEO, Gokaldas Exports

Mrs Jyotsna Govil
Chairperson, ICS Delhi Branch

Mr Kishore Rao
Chairman, ICS Bengaluru Branch

Dr Shailesh Ayyangar
Former MD, Sanofi India

Dr Anant Gokarn
Professor Dept. of Medical Oncology

Dr Avinash Deo
Medical Oncologist

Every application is first screened by the AI tool followed by a medical Due Diligence Team, chaired by **Dr. Nehal Khanna** Prof. Radiation Oncologist

Source: Indian Cancer Society
Refer disclaimers on slide 19

Presenting **HDFC Charity Fund for Cancer Cure (Feb 2030)**

A close-ended debt scheme (Fixed Maturity Plan) that turns part of your investment income into treatment support for underprivileged cancer patients, in partnership with the Indian Cancer Society.

Fixed Maturity Plan

Invests in debt & money-market instruments

Built-in Purpose

50% or 75% of IDCW will be donated to ICS

Matched by HDFC AMC

Every rupee donated will be matched, doubling the impact*

No Investment management fee by the AMC

The Scheme being a philanthropic initiative by the AMC, no investment management and advisory fee shall be charged by the AMC^

NFO opens: **16-Nov-2026** | NFO closes: **30-Nov-2026**

*Subject to a limit of Rs 16 crores per financial year. IDCW - Income Distribution and Capital Withdrawal, ^It is proposed to charge a nominal base expense ratio of 3 basis points (bps) to the Scheme towards expenses like investor education, awareness and financial inclusion and any expenses incurred beyond 3 bps and all distribution expenses shall be borne / reimbursed fully by the AMC.

Refer disclaimers on slide 19

Why should you invest?

A cause you can see

A unique mutual fund scheme that lets you contribute to a visible cause.

Investing + philanthropy

Combine your investment and your giving in one scheme.

Income that heals

Part of your distribution income* goes to the Indian Cancer Society to treat underprivileged cancer patients.

Your choice

Donate 50% or 75% of your IDCW.



*IDCW - Income Distribution and Capital Withdrawal

Refer disclaimers on slide 19

One investment. Two outcomes.

01 You invest

Invest in the NFO; sign a one-time donation mandate.

02 Fund invests

1169-day FMP which invests in debt and money markets.

03 Income paid

IDCW declared periodically.

04 Donation to ICS

Based on selected option, 50% or 75% of IDCW donation to ICS based on OTM^



For the patient

Support Treatment



For individuals

Tax benefit* on IDCW Donation under Sec 133 of Income Tax Act 2025 (Old Regime)



For corporates

IDCW Donation counts towards CSR*

*Donation to ICS contributed via IDCW may qualify for corporate investors' Corporate Social Responsibility (CSR) subject to their respective CSR agenda/policy, for which investors need to get in touch with ICS directly. Donation of income to ICS is eligible for claiming of deduction U/s 133 of Income Tax Act, 2025 under the old regime. ^ICS will initiate donation debits from Unit holders' bank accounts under the one-time mandate (OTM) provided by the investor in favour of ICS. After IDCW is disbursed, HDFC AMC will advise ICS of the amount to be deducted for each Unit holder, based on gross IDCW and the investor's selected option (50% or 75%).

Refer disclaimers on slide 19

Aim and Give a bit extra



Tax deduction^

Donated income is eligible u/s 133 of Income Tax Act 2025, (old regime); ICS will issue certificates.



CSR-eligible^

Corporates can count the IDCW contribution towards CSR - Preventive Healthcare, Schedule VII, Companies Act 2013.



2x impact

HDFC AMC will match your donation amount*



No Investment management fee

The Scheme being a philanthropic initiative by the AMC, no investment management and advisory fee shall be charged by the AMC#



Maturity Proceeds

Only 50% or 75% of the IDCW is donated; redemption proceeds at maturity come to you.

*Subject to a limit of Rs 16 crores per financial year. ^Tax and CSR treatment is subject to applicable laws and on each investor's individual circumstances. Investors are advised to consult their tax advisors. #it is proposed to charge a nominal base expense ratio of 3 basis points (bps) to the Scheme towards expenses like investor education, awareness and financial inclusion and any expenses incurred beyond 3 bps and all distribution expenses shall be borne / reimbursed fully by the AMC.

Refer disclaimers on slide 19

Scheme Features

Name of the Scheme	HDFC Charity Fund for Cancer Cure (Feb 2030)
Type of Scheme	A Close Ended Income Scheme with Tenure of 1169 Days. A Relatively High Interest Rate Risk and Relatively Low Credit Risk.
Investment Objective	To generate income through investments in Debt / Money Market Instruments and Government Securities maturing on or before the maturity date of the Scheme. **There is no assurance that the investment objective of the Scheme will be achieved.**
Benchmark Index	NIFTY Medium Duration Debt Index A-III
Fund Manager	Mr. Anil Bamboli, Mr. Gopal Agrawal (Overseas Investments)
Investment Plans	▪ **Direct Plan** ▪ **Regular Plan**
Investment Options	Under Each Plan only Payout of Income Distribution cum Capital Withdrawal (IDCW) Option with the following sub - options ▪ 50% IDCW Donation Option ▪ 75% IDCW Donation Option
Minimum Application Amount	**During NFO Period** **Purchase**: Rs. 50,000/- and in multiples of Rs.1,000/- thereafter per application Note: Allotment of units will be done after deduction of applicable stamp duty and transaction charges, if any.
Load Structure	**Entry Load: No entry load will be charged.** **Exit Load**: Not applicable
Investment Management and Advisory Fee	No investment management and advisory fee shall be charged by the AMC. A nominal base expense ratio of 3 basis points (bps) shall be charged to the Scheme, and any expenses incurred beyond 3 bps, along with all distribution expenses, shall be fully borne or reimbursed by the AMC.

For further details, refer Scheme Information Document and Key Information Memorandum available on www.hdfcfund.com and at Investor Service Centres of HDFC Mutual Fund

Refer disclaimers on slide 19

Asset Allocation

Under normal circumstances, the asset allocation of the scheme's portfolio will be as follows:

Type of Instruments	Indicative Allocations (% of Total Assets)	
	Minimum	Maximum
Debt Instruments, Money Market Instruments and Government Securities	0	100
Units of debt mutual fund Schemes	0	5

The schemes debt and money market instruments are subject to Credit, Interest-rate, Liquidity, Concentration and Market risk. The fund will establish issuer/group limits, undertake credit due diligence prior to investments, monitor credit ratings, monitor the portfolio duration and interest-rate sensitivity, conduct stress testing and maintain appropriate liquidity buffers so as to align asset pay-outs with expected cash outflows. As a closed ended scheme, the intent is to hold instruments to maturity, subject to risk driven adjustments in line with SEBI mandated controls and rebalancing requirements.

Refer disclaimers on slide 19


Riskometer & PRC

HDFC Charity Fund for Cancer Cure (Feb 2030) is suitable for investors who are seeking*

- To generate regular income over the tenure of the Scheme 1169 days term.
- Investments in Debt/Money Market Instruments and Government Securities.

*Investors should consult their financial advisers, if in doubt about whether the product is suitable for them.
#The product labeling assigned during the NFO is based on internal assessment of the scheme. For latest riskometer, investors may refer to the Monthly Portfolios disclosed on the website of the Fund viz. **www.hdfcfund.com**

Riskometer #




The risk of the scheme is moderate

Potential Risk Class (PRC) (Maximum risk the Scheme can take)

Credit Risk → / Interest Rate Risk ↓	**Relatively Low (Class A)**	**Moderate (Class B)**	**Relatively High (Class C)**
Relatively Low (Class I)			
Moderate (Class II)			
Relatively High (Class III)	**A-III**		

A-III - A Scheme with Relatively High Interest Rate Risk and Relatively Low Credit Risk

Refer disclaimers on slide 19



"May all be happy. May all be free from illness."

Refer disclaimers on slide 19

Disclaimer

This presentation dated 29th October, 2026 has been prepared by HDFC Asset Management Company Limited (HDFC AMC) based on internal data, publicly available information and other sources believed to be reliable. Any calculations made are approximations, meant as guidelines only, which you must confirm before relying on them. The information contained in this document is for general purposes only. The document is given in summary form and does not purport to be complete. The document does not have regard to specific investment objectives, financial situation and the particular needs of any specific person who may receive this document. The information/ data herein alone are not sufficient and should not be used for the development or implementation of an investment strategy. The statements contained herein are based on our current views and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The information pertaining to the Indian Cancer Society (ICS) and the patients has been compiled by the ICS. Neither HDFC AMC and HDFC Mutual Fund nor any person connected with them, accepts any liability arising from the use of this document. The recipient(s) before acting on any information herein should make his/her/their own investigation and seek appropriate professional advice and shall alone be fully responsible / liable for any decision taken on the basis of information contained herein.

NSE and BSE Disclaimer:

It is to be distinctly understood that the permission given by National Stock Exchange of India Limited (NSE)/ BSE Limited (BSE) should not in any way be deemed or construed that the Scheme Information Document (SID) has been cleared or approved by NSE/ BSE nor does it certify the correctness or completeness of any of the contents of the SID. The investors are advised to refer to the SID for the full text of the Disclaimer clause of NSE/ BSE.

HDFC Bank (Sponsor of HDFC Mutual Fund) is not liable or responsible for any loss or shortfall resulting from the operations of the scheme.

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKETS RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

Mission: To be the wealth creator for every Indian

Vision: To be the most respected asset manager in the world